Literature DB >> 4072624

Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.

A Bardosi, P Scheidt, H H Goebel.   

Abstract

A 66-year-old man had developed a myopathy while undergoing several periods of etofibrate and clofibrate therapy over the past 5 years. Discontinuation of etofibrate treatment failed to reverse his muscle illness which, however, did not progress. A muscle biopsy revealed a chronic myopathy marked by abundant, abnormally structured muscle mitochondria. His mitochondrial myopathy may represent a forme fruste of the Kearns-Sayre syndrome or other types of mitochondrial myopathy, clinically made evident by the etofibrate/clofibrate therapy, or a permanent, adverse side effect of clofibrate treatment. If the latter assumption proves to be correct, it will indicate that clofibrate therapy may induce an acutely painful but reversible neuromuscular illness, or also, though rarely, a chronic mitochondrial myopathy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4072624     DOI: 10.1007/BF00688640

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

1.  Clofibrate, nephrotic syndrome, and histological changes in muscle.

Authors:  M Denizot; J Fabre; D Pometta; E Wildi
Journal:  Lancet       Date:  1973-06-09       Impact factor: 79.321

2.  Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.

Authors:  J F Bridgman; S M Rosen; J M Thorp
Journal:  Lancet       Date:  1972-09-09       Impact factor: 79.321

3.  Muscular syndrome after clofibrate.

Authors:  N Katsilambros; J Braaten; B D Ferguson; R F Bradley
Journal:  N Engl J Med       Date:  1972-05-18       Impact factor: 91.245

4.  Acute muscular syndrome associated with administration of clofibrate.

Authors:  T Langer; R I Levy
Journal:  N Engl J Med       Date:  1968-10-17       Impact factor: 91.245

5.  Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy.

Authors:  A G Smals; L V Beex; P W Kloppenborg
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

6.  Letter: Clofibrate-induced myopathy syndrome.

Authors:  K W Rumpf; R Albers; F Scheler
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

7.  Involvement of transverse tubules in induced myotonia.

Authors:  M Ontell; H S Paul; S A Adibi; J L Martin
Journal:  J Neuropathol Exp Neurol       Date:  1979-11       Impact factor: 3.685

8.  Clofibrate-induced muscle damage in patients with chronic renal failure.

Authors:  A M Pierides; F Alvarez-Ude; D N Kerr
Journal:  Lancet       Date:  1975-12-27       Impact factor: 79.321

9.  Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations.

Authors:  N Abourizk; B A Khalil; N Bahuth; A K Afifi
Journal:  J Neurol Sci       Date:  1979-06       Impact factor: 3.181

10.  Mode of inhibition of mitochondrial energy transduction by chlorophenoxyisobutyrate.

Authors:  S R Panini; C K Kurup
Journal:  Biochem J       Date:  1974-08       Impact factor: 3.857

View more
  5 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 2.  Secondary mitochondrial pathology.

Authors:  R C Sengers; A M Stadhouders
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

3.  Adult-onset mitochondrial myopathy.

Authors:  J Fernandez-Sola; J Casademont; J M Grau; F Graus; F Cardellach; E Pedrol; A Urbano-Marquez
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

Review 4.  On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

5.  Myopathy with ragged red fibres following renal transplantation: possible role of cyclosporin-induced hypomagnesaemia.

Authors:  A J Larner; S G Sturman; J B Hawkins; M Anderson
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.